Low back pain is a common problem among competitive swimmers, and repeated torso hyperextension is claimed to be an etiological factor. The purpose of this study was to describe the three-dimensional torso configurations in the front crawl stroke and to test the hypothesis that swimmers experience torso hyperextension consistently across the stroke cycles. Nineteen collegiate swimmers underwent 2 measurements: a measurement of the active range of motion in 3 dimensions and a measurement of tethered front crawl stroke at their maximal effort. Torso extension beyond the active range of torso motion was defined as torso hyperextension. The largest torso extension angle exhibited during the stroke cycles was 9 ± 11° and it was recorded at or around 0.02 ± 0.08 s, the instant at which the torso attained the largest twist angle. No participant hyperextended the torso consistently across the stroke cycles and subjects exhibited torso extension angles during tethered front crawl swimming that were much less than their active range of motion. Therefore, our hypothesis was rejected, and the data suggest that repeated torso hyperextension during front crawl strokes should not be claimed to be the major cause of the high incidence of low back pain in swimmers.
Purpose Although visual field testing is conducted with the subject gazing at a fixation target, constant minute eye movements, called fixational eye movements, do occur during fixation. We examined dynamic changes in fixational eye movements associated with stimulus presentation during visual field testing. Methods We used the head-mounted perimeter imo, which is capable of measurement under binocular conditions, with the frame rate of its fixation monitoring camera improved to 300 Hz, to assess fixational eye movements in 18 healthy individuals. We measured changes in fixational eye movements during testing under monocular and binocular conditions and analyzed these changes based on the bivariate contour ellipse area (BCEA). We also assessed the changes in the horizontal and vertical microsaccade rates separately. Results Both the BCEA and horizontal microsaccade rates were higher at 400 to 600 msec after stimulus presentation than during stimulus presentation ( P < 0.01). Additionally, the BCEA and vertical microsaccade rates were significantly lower in the binocular condition than in the monocular condition ( P < 0.01 and P < 0.05, respectively). We did not observe a significant correlation between the test locations and microsaccade direction during visual field testing. Conclusions Fixational eye movements, especially vertical microsaccade rates, were lower in the binocular condition than in the monocular condition. Visual field testing under binocular conditions is a useful method for suppressing fixational eye movements and stabilizing the fixation during testing and may improve the reliability of the test results. Translational Relevance Visual field testing under binocular conditions can make the fixation more stable during the testing compared with monocular conditions.
Purpose To investigate the factors that affected the total occlusion time (TOT) in eyes with hyperopic anisometropic amblyopia. Methods Subjects were 58 patients (26 boys and 32 girls; age range, 3.6-9.2, average, 5.8 ± 1.3 years) with hyperopic anisometropic amblyopia. All the subjects had initially visited and completed occlusion therapy with improved visual acuity (VA) of 1.0 (0.0 logMAR equivalent) or better in the amblyopic eye at Kindai University Hospital between January 2007 and March 2017. Using the subjects’ medical records, five factors for the TOT were evaluated retrospectively: the age at treatment, the initial VA of the amblyopic eye, refraction of the amblyopic eye, anisometropic disparity, and the presence of microstrabismus. Results The initial VA of the amblyopic eye ranged from 0.1 to 0.9 (median, 0.4). The TOT ranged from 140 to 1795 (median, 598) hours with an average daily occlusion time of 7 hours. The initial VA of the amblyopic eye and presence of microstrabismus were the influential factors for the TOT (p< 0.01). To achieve VA of 1.0 or better, patients with initial VA of ≤ 0.3 in the amblyopic eye required a longer TOT. Moreover, patients with concomitant microstrabismus required a 1.7-fold longer TOT compared to those without microstrabismus. Conclusion Patient’s initial VA and the presence of microstrabismus are the significant factors that affect the TOT.
Purpose To investigate the factors that affected the total occlusion time (TOT) in eyes with hyperopic anisometropic amblyopia. Methods Subjects were 58 patients (26 boys and 32 girls; age range, 3.6-9.2, average, 5.8 ± 1.3 years) with hyperopic anisometropic amblyopia. All the subjects had initially visited and completed occlusion therapy with improved visual acuity (VA) of 1.0 (0.0 logMAR equivalent) or better in the amblyopic eye at Kindai University Hospital between January 2007 and March 2017. Using the subjects’ medical records, five factors for the TOT were evaluated retrospectively: the age at treatment, the initial VA of the amblyopic eye, refraction of the amblyopic eye, anisometropic disparity, and the presence of microstrabismus. Results The initial VA of the amblyopic eye ranged from 0.1 to 0.9 (median, 0.4). The TOT ranged from 140 to 1795 (median, 598) hours with an average daily occlusion time of 7 hours. The initial VA of the amblyopic eye and presence of microstrabismus were the influential factors for the TOT (p< 0.01). To achieve VA of 1.0 or better, patients with initial VA of ≤ 0.3 in the amblyopic eye required a longer TOT. Moreover, patients with concomitant microstrabismus required a 1.7-fold longer TOT compared to those without microstrabismus. Conclusion Patient’s initial VA and the presence of microstrabismus are the significant factors that affect the TOT.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.